Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention

Journal of Clinical Pharmacology

Volumn 44, Issue 9, 2004, Pages 981-990

  Cox, Donna S ^a   Kleiman, Neal S ^d   Boyle, Duane A ^a   Aluri, Jagadeesh ^a   Parchman, L Gerald ^b   Holdbrook, Frederick ^c   Fossler, Michael J ^a  

^a GLAXOSMITHKLINE   (United States)

^b Clin Devmt and Medical Affairs   (United States)

^c Biomed Data Sci Biostatist/Prog   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Activated clotting time; Argatroban; Percutaneous coronary intervention; Pharmacodynamics; Pharmacokinetics; Platelet GPIIb IIIa receptor antagonists

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

ARTICLE; BLOOD CLOTTING TIME; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ALGORITHMS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; WHOLE BLOOD COAGULATION TIME;

EID: 4143054608     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004267651     Document Type: Article

References (31)

1. McKeage K, Plosker G: Argatroban. Drugs 2001;61:515-522.
2. Wittkowsky AK: The role of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy 2002;22(6, Pt. 2): 97S-104S.
3. Ruef J, Katus HA: New antithrombotic drugs on the horizon. Expert Opin Pharmacother 2003;12:781-797.
4. Choo JK, Yong JJ, Kereiakes DJ: A guide to drug use during percutaneous coronary intervention. Drugs 2002;62:2589-2601.
5. Kaplan K: Direct thrombin inhibitors. Expert Opin Pharmacother 2003;4:653-666.
6. Popma JJ, Ohman M, Weitz J, Lincoff M, Harrington, RA, Berger P: Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001;119:321S-336S.
7. Popma JJ, Weitz J, Bittl JA, Ohman M, Kuntz RE, Lansky AJ, et al: Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998;114:728S-741S.
8. Eikelboom J, French J: Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors? Drugs 2002;62:1839-1852.
9. Mehta WR, Yusuf S: Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41:79S-88S.
10. Cohen M: The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol 2003;41: 55S-61S.
11. Nappi J: Heparin, bivalirudin, and reduction of complications during percutaneous coronary intervention. Pharmacotherapy 2002; 22(6, Pt. 2):89S.
12. Deutsch E: The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory. Am Heart J 1999;138:S577-S585.
13. Tcheng JE, Talley D. OShea J, Gilchrist I, Kleiman N, Grines C. et al: Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (The PRIDE study). Am J Cardiol 2001;88:1097-1102.
14. Kleiman N, Llem J, Fernandes L, Rubin H, Challa S, Solomon S, et al: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002;143:585-593.
15. Gilchrist I, Oshea C, Kosoglou T, Jennings L, Lorenz T, Kitt M. et al: Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104:406-411.
16. Bauer KA: Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost 2002;28(Suppl. 2): 15-24.
17. Hirsh J: New anticoagulants. Am Heart J 2001;2(Supp.):S3-S8.
18. Hursting MJ, Alford K, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, et al: Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Sem Thromb Hemost 1997:23: 503-516.
19. Moledina M, Chakir M, Gandhi PJ: A synopsis of the clinical uses of argatroban. J Thromb Thrombolysis 2001;12:141-149.
20. Swan SK, Hursting MJ: The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329.
21. Lewis BE, Matthai WH Jr, Cohen M, Moses J, Hursting M, Leya, F: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-184.
22. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walengo JM, et al: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
23. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Int Med 2003;163:1849-1856.
24. Jang IK, Lewis BE, Matthai WH, Kleiman NS: Argatroban and glycoprotein IIb/IIIa inhibitor are effective and safe in patients undergoing percutaneous coronary intervention: a prospective, open-label, dose-response study [abstract]. Am J Cardiol 2003;92(Suppl.):128L.
25. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1996;336:1689-1696.
26. Reginelli JP, Chew D: Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition. J Interv Cardiol 2002;15:141-146.
27. Tran JQ, DiCicco RA, Sheth SB, Tucci M, Peng L, Jorkasky DL, et al: Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999;39:513-519.
28. Inglis AM, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco RA: Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin. Am J Health Syst Pharm 2002; 59:1258-1266.
29. Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J: Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost 2002;8:217-224.
30. Prescribing information for argatroban. Accessed May 19, 2004, at www.argatroban.com
31. Swan SK, St. Peter JV, Lambrecht LJ, Hursting MJ: Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20:756-770.